2026-04-14T06:44:22Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/136892025-09-30T02:07:32Zcom_2072_378070com_2072_378040col_2072_378092

Secondary resistance to sonidegib is rare in locally advanced basal cell carcinoma BAURAIN, JEAN-FRANCOIS Martelli, Serena Arntz, Ramon Savoia, Paola MUÑOZ COUSELO, EVA Berking, Carola Institut Català de la Salut [Muñoz Couselo E] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Berking C] Department of Dermatology, Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany. Comprehensive Cancer Center Erlangen—European Metropolitan Area of Nürnberg (CCC ER-EMN), Erlangen, Germany. Bavarian Cancer Research Center (BZKF), Uniklinikum Erlangen, Erlangen, Germany. [Baurain JF] Institut Roi Albert II, Cliniques Universitaires SaintLuc, Université Catholique de Louvain, Brussels, Belgium. Institute for Experimental and Clinical Research, Université Catholique de Louvain, Brussels, Belgium. [Martelli S, Arntz R] Sun Pharmaceutical Industries B.V., Hoofddorp, The Netherlands. [Savoia P] Department of Health Sciences, University of Eastern Piedmont, Novara, Italy Vall d'Hebron Barcelona Hospital Campus Medicaments antineoplàstics - Ús terapèutic - Efectes secundaris Carcinoma basocel·lular - Tractament DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Glandular and Epithelial::Carcinoma::Carcinoma, Basal Cell Other subheadings::Other subheadings::Other subheadings::/drug therapy CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents Other subheadings::Other subheadings::Other subheadings::/adverse effects ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias glandulares y epiteliales::carcinoma::carcinoma basocelular Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos Secondary resistance; Locally advanced basal cell carcinoma Resistencia secundaria; Carcinoma basocelular localmente avanzado Resistència secundària; Carcinoma basocel·lular localment avançat The BOLT study was sponsored and funded by Novartis; this analysis was funded by Sun Pharma. Medical writing and editorial support were funded by Sun Pharma Europe B.V. 2025-09-19T08:25:45Z 2025-09-19T08:25:45Z 2025-09 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Muñoz Couselo E, Berking C, Baurain JF, Martelli S, Arntz R, Savoia P. Secondary resistance to sonidegib is rare in locally advanced basal cell carcinoma. J Eur Acad Dermatology Venereol. 2025 Sep;39(9):e788–90. 1468-3083 http://hdl.handle.net/11351/13689 10.1111/jdv.20629 40055950 001439777700001 http://hdl.handle.net/11351/13689 eng Journal of the European Academy of Dermatology and Venereology;39(9) https://doi.org/10.1111/jdv.20629 Attribution-NonCommercial 4.0 International http://creativecommons.org/licenses/by-nc/4.0/ info:eu-repo/semantics/openAccess application/pdf Wiley Scientia